Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 33 of 5804
-
Heat, not surgery: new trial aims to cure thyroid cancer without a knife
⭐️ CURE ⭐️ Recruiting nowThis pilot, single-arm clinical study evaluates the feasibility, safety, and effectiveness of radiofrequency ablation (RFA) as a curative treatment for small, low-risk papillary thyroid cancer (PTC). The study will enroll 30 adult patients (≥18 years) with biopsy-confirmed PTC me…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:35 UTC
-
Could a pill save insulin cells? new trial for kids and young adults with type 1 diabetes
Disease control Recruiting nowThe purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Simple blood test could spot pancreatic cancer before symptoms start
Diagnosis Recruiting nowThis nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer screening in Japan. Approximately 10,000 asymptomatic adults will be enrolled. Participants with an Enzeavo…
Phase: NA • Sponsor: Cosomil, Inc. • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Tough-to-Treat myeloma: phase 3 trial launches
Disease control Recruiting nowThe purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
HIV prevention breakthrough? Twice-Yearly shot could replace daily pills
Prevention Recruiting nowThe goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil. The study will also learn about safety, continued use over time, and whether people prefer this opt…
Phase: NA • Sponsor: Oswaldo Cruz Foundation • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
New targeted therapy combo aims to fight stubborn stomach cancers
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesop…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Brain cancer breakthrough? new CAR-NK cell trial targets glioblastoma
Disease control Recruiting nowThis is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent or progressive glioblastoma (GBM) or other high-gr…
Phase: PHASE1 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Weekly shot shows promise for major weight loss in obesity trial
Disease control Recruiting nowThis Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes w…
Phase: PHASE3 • Sponsor: Hudson Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New RSV prevention strategy for infants under study in bogotá
Prevention Not yet recruitingThis study aims to evaluate the real-world effectiveness of two preventive immunization strategies against Respiratory Syncytial Virus (RSV)-associated severe acute respiratory infection in infants less than six months of age in Bogotá, Colombia. The strategies include maternal v…
Sponsor: Bogotá District Health Secretariat • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
New CAR T-Cell therapy targets tough blood cancers
Disease control Recruiting nowThis is a phase I/II trial of T-cell expressing an anti-CD22 Chimeric-Antigen-Receptor (CAR) in patients with CD22 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed/refractory B-cell malignancies.
Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Triple threat: radiation and immunotherapy join chemo against pancreatic cancer
Disease control Not yet recruitingThis Phase III randomized trial, evaluates whether adding targeted radiation (SBRT) and an immunotherapy drug (Serplulimab) to standard chemotherapy (GnP) can extend the lives of patients with advanced pancreatic cancer.
Phase: PHASE3 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental CAR-T therapy takes aim at Hard-to-Treat lupus kidney disease
Disease control Not yet recruitingThe purpose of this clinical trial is to evaluate the safety and efficacy of CRC01, an investigational autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, in people with lupus nephritis (LN), a serious kidney complication of systemic lupus erythematosus (SLE). …
Phase: PHASE1, PHASE2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Off-the-Shelf cell therapy takes on tough leukemia
Disease control Not yet recruitingAcute myeloid leukemia (AML) is a common type of acute leukemia in adults. Although the treatment of AML has improved in recent decades, the 5-year survival rate remains below 50% due to the chemoresistance or toxicity of these treatments. Most patients eventually die from relaps…
Phase: PHASE1 • Sponsor: Mingfeng Zhao • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can pridopidine slow ALS? major trial underway
Disease control Recruiting nowThe goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Rese…
Phase: PHASE3 • Sponsor: Prilenia • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New stroke drug could boost recovery when given hours after symptoms
Disease control Not yet recruitingThis randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well…
Phase: PHASE3 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on tough leukemia in new trial
Disease control Not yet recruitingThis study is a clinical trial designed to evaluate the safety and efficacy of a new type of CAR-T cell therapy for patients with relapsed/refractory acute myeloid leukemia (AML). The treatment involves modifying the patient's own T cells to target and eliminate leukemia cells mo…
Phase: PHASE1, PHASE2 • Sponsor: Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on stubborn anemia
Disease control Not yet recruitingThis study is an open-label, single-arm, prospective, multicenter, phase I/II clinical trial. It adopts the two-stage optimal design proposed by Bryant and Day to investigate the efficacy, safety, and in vivo pharmacokinetic characteristics of CD19/BCMA CAR-T cell therapy in the …
Phase: PHASE1, PHASE2 • Sponsor: Yihao Wang • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a shot every 6 months end HIV? new study tests lenacapavir in south africa
Prevention Not yet recruitingThe ALIGN study will evaluate the delivery of injectable Lenacapavir (LEN), a long-acting injectable formulation for HIV pre-exposure prophylaxis (PrEP), amongst adolescents and young people (aged 15-35 years) living within the Klipfontein-Mitchell's health sub-district of Cape T…
Sponsor: Desmond Tutu HIV Foundation • Aim: Prevention
Last updated Jun 27, 2026 09:02 UTC
-
Can this IV drug help avoid liver transplants in heavy drinkers?
Disease control Recruiting nowThe primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater t…
Phase: PHASE3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Magic mushroom microdoses could soothe End-of-Life anxiety
Symptom relief Recruiting nowAbout 30-50% of patients with advanced illness experience depression, anxiety, or decreased sense of purpose and autonomy. Together, these are called psychological distress. Treatment options such as medication and therapy are available; however, they do not always work and can b…
Phase: PHASE3 • Sponsor: Bruyère Health Research Institute. • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC